Shriner KA - Search Results

1

An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse.

Wong-Beringer A, Nguyen LH, Lee M, Shriner KA, Pallares J. Wong-Beringer A, et al. Among authors: shriner ka. Pharmacotherapy. 2009 Jun;29(6):736-43. doi: 10.1592/phco.29.6.736. Pharmacotherapy. 2009. PMID: 19476424

2

Fluconazole-induced agranulocytosis with eosinophilia.

Wong-Beringer A, Shriner K. Wong-Beringer A, et al. Pharmacotherapy. 2000 Apr;20(4):484-6. doi: 10.1592/phco.20.5.484.35058. Pharmacotherapy. 2000. PMID: 10772380

3

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Hidayat LK, et al. Among authors: shriner ka. Arch Intern Med. 2006 Oct 23;166(19):2138-44. doi: 10.1001/archinte.166.19.2138. Arch Intern Med. 2006. PMID: 17060545

4

Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome.

Nguyen LH, Hsu DI, Ganapathy V, Shriner K, Wong-Beringer A. Nguyen LH, et al. J Antimicrob Chemother. 2008 Mar;61(3):714-20. doi: 10.1093/jac/dkm510. Epub 2008 Jan 25. J Antimicrob Chemother. 2008. PMID: 18222951

5

Regulatory oversight and safety of probiotic use.

Venugopalan V, Shriner KA, Wong-Beringer A. Venugopalan V, et al. Among authors: shriner ka. Emerg Infect Dis. 2010 Nov;16(11):1661-5. doi: 10.3201/eid1611.100574. Emerg Infect Dis. 2010. PMID: 21029521 Free PMC article.

6

Can clinical and molecular epidemiologic parameters guide empiric treatment with vancomycin for methicillin-resistant Staphylococcus aureus infections?

Yamaki J, Lee M, Shriner KA, Wong-Beringer A. Yamaki J, et al. Among authors: shriner ka. Diagn Microbiol Infect Dis. 2011 May;70(1):124-30. doi: 10.1016/j.diagmicrobio.2010.12.003. Epub 2011 Mar 9. Diagn Microbiol Infect Dis. 2011. PMID: 21392923

7

Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.

Joo J, Yamaki J, Lou M, Hshieh S, Chu T, Shriner KA, Wong-Beringer A. Joo J, et al. Among authors: shriner ka. Clin Ther. 2013 Jul;35(7):995-1004. doi: 10.1016/j.clinthera.2013.05.018. Epub 2013 Jul 2. Clin Ther. 2013. PMID: 23829982

8

Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.

Sullivan E, Bensman J, Lou M, Agnello M, Shriner K, Wong-Beringer A. Sullivan E, et al. Crit Care Med. 2014 Jan;42(1):48-56. doi: 10.1097/CCM.0b013e318298a86f. Crit Care Med. 2014. PMID: 23963124

9

Factors associated with prompt recovery among hospitalised patients with coronavirus disease 2019.

Ny P, Kelsom C, Chron A, Lou M, Nieberg P, Shriner K, Huse H, Wong-Beringer A. Ny P, et al. Int J Clin Pract. 2021 Nov;75(11):e14818. doi: 10.1111/ijcp.14818. Epub 2021 Sep 20. Int J Clin Pract. 2021. PMID: 34487380 Free PMC article.

10

Unvaccinated Non-Elderly Adult Population Hospitalized for COVID-19: Risk for Severe Disease and Poor Outcomes.

Jo D, Sophonsri A, Ny P, Lou M, Nieberg P, Shriner K, Wong-Beringer A. Jo D, et al. J Prim Care Community Health. 2022 Jan-Dec;13:21501319221119138. doi: 10.1177/21501319221119138. J Prim Care Community Health. 2022. PMID: 35978558 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters